- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Challenge Accepted: OHSU Seeks $500 Million to Match Cancer Research Pledge
24 September 2013 6:15 pm
Let the fundraising begin! At a press briefing today, Oregon Health & Science University (OHSU) officials announced their intent to raise $500 million for cancer research over the next 2 years in order to earn an equivalent matching grant. The $500 million challenge was offered last Friday in a surprise move by philanthropists Phil and Penny Knight. The $1 billion campaign “is a transformational moment” for the university and the war on cancer, says OHSU President Joe Robertson.
The Knights had previously donated $100 million to create a cancer research institute at OHSU, headed by Brian Druker, who led the development of the cancer drug Gleevec. Their latest pledge came after Druker recently lobbied the couple for another $1 billion to take insights from Gleevec, as well as other so-called molecularly targeted therapies, and develop better early detection tools for tumors. Calling current cancer detection methods “relatively crude technologies,” Druker says “we have to do better.”
OHSU officials didn’t offer specifics for how they plan to spend the potential $1 billion, although Druker says he envisions hiring about 20 elite scientists and giving them enough funding to take risks, a strategy he compared to what the Howard Hughes Medical Institute does. “We’re trying to release investigators from our current constraints of grant-writing,” he says.
Phil Knight was a co-founder of athletic shoe giant Nike and is now a prominent funder of academia. In 2006, he gave Stanford University’s business school what was, at that time, the largest donation in its history, $105 million.